Human medicines

Recall of Jakavi 15 mg tablets due to suspected counterfeiting

Safety warnings | Medicines | 25/10/2018
No acute danger, recall purely as a precautionary measure
Recall of Jakavi 15 mg tablets due to suspected counterfeiting Read more

BCG, mitomycin, mito-extra

Recall | Medicines | 11/10/2018

The marketing authorization holder informed the supplied customers via its distribution partner in a letter dated 01.10.2018 that the urology…

BCG, mitomycin, mito-extra Read more

Jakavi

Recall | Medicines | 08/10/2018

The parallel distributor - "HAEMATO PHARM GmbH" - informed its supplied customers in a letter dated October 8, 2018, that for the two batches of…

Jakavi Read more

Robinul

Recall | Medicines | 16/08/2018

The marketing authorization holder informed its supplied customers in a letter dated August 16, 2018, that due to quality problems with one batch of…

Robinul Read more

CO-Valsax and Valsartan-HCT from G.L. Pharma GmbH

Recall | Medicines | 14/08/2018

The marketing authorization holder informed its supplied customers in a letter dated July 5, 2018, that a production-related impurity occurred at the…

CO-Valsax and Valsartan-HCT from G.L. Pharma GmbH Read more

Valsartan medication review - update.

Safety warnings | Medicines | 03/08/2018
Preliminary risk assessment of NDMA for patients
Valsartan medication review - update. Read more

Valsartan and Valsartan/HCT from 1A Pharma GmbH

Recall | Medicines | 06/07/2018

The marketing authorization holder informed its supplied customers in a letter dated 06.07.2018 that a production-related contamination of the active…

Valsartan and Valsartan/HCT from 1A Pharma GmbH Read more

Valsartan and Valsartan/HCT from Sandoz GmbH

Recall | Medicines | 06/07/2018

In a letter dated July 6, 2018, the marketing authorization holder informed its customers that a production-related contamination of the active…

Valsartan and Valsartan/HCT from Sandoz GmbH Read more

Valsartan and Valsarcomp from Genericon Pharma GmbH

Recall | Medicines | 05/07/2018

The marketing authorization holder has informed its supplied customers in a letter dated July 4, 2018, that the active ingredient valsartan may…

Valsartan and Valsarcomp from Genericon Pharma GmbH Read more
Email

Further inquiry note